Breaking News, Collaborations & Alliances

Novo Nordisk, Evotec Select First LAB eN² Projects for Discovery Accelerator

First three selected projects will focus on research for different cardiometabolic conditions.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Evotec’s translational drug discovery accelerator with Novo Nordisk, LAB eN², which aims to support early research from academic institutions into therapeutics, has selected its first three projects to advance in the program from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center. LAB eN² is also expanding to include five additional academic institutions: Boston Children’s Hospital, Boston University, Johns Hopkins University, Joslin Diab...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters